High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT) ± surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory.

[1]  Takashi Yoshida,et al.  Immune reconstitution of B‐cell lymphoma patients receiving CHOP‐based chemotherapy containing rituximab , 2011, Hematological oncology.

[2]  M. Ozsahin,et al.  Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Giné,et al.  Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era , 2010, Leukemia & lymphoma.

[4]  C. Tam,et al.  High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone , 2010, Leukemia & lymphoma.

[5]  S. Roman,et al.  Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. , 2009, Surgery.

[6]  L. Foppiani,et al.  Thyroid lymphoma: a rare tumor requiring combined management , 2009, Hormones.

[7]  Tae Yong Kim,et al.  Clinical characteristics of primary thyroid lymphoma in Koreans. , 2009, Endocrine journal.

[8]  A. Saxena,et al.  Clonal relationship between Hashimoto thyroiditis and thyroid lymphoma , 2007, Journal of Clinical Pathology.

[9]  H. Nakamine,et al.  Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  T. Molina,et al.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Pasieka,et al.  Anaplastic thyroid cancer and primary thyroid lymphoma: A review of these rare thyroid malignancies , 2006, Journal of surgical oncology.

[13]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[14]  R. Greil,et al.  Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: Case report and review of the literature , 2006, Leukemia & lymphoma.

[15]  P. Zinzani,et al.  Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2006, Haematologica.

[16]  J. Coebergh,et al.  Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. , 2005, Clinical lymphoma & myeloma.

[17]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[18]  J. Pasieka,et al.  An Evidence-Based Approach to the Treatment of Thyroid Lymphoma , 2007, World Journal of Surgery.

[19]  R. Kanthan,et al.  Clonal B cell populations in a minority of patients with Hashimoto’s thyroiditis , 2004, Journal of Clinical Pathology.

[20]  J. Earle,et al.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Grigsby,et al.  Outcome Analysis for Stage IE and IIE Thyroid Lymphoma , 2004, American journal of clinical oncology.

[22]  R. Mertelsmann,et al.  Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology , 2004, Annals of Hematology.

[23]  R. Fisher,et al.  Diffuse aggressive lymphoma. , 2004, Hematology. American Society of Hematology. Education Program.

[24]  R. Tsang,et al.  Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[26]  G. Martinelli,et al.  ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma , 2003, Leukemia & lymphoma.

[27]  F. Cavalli,et al.  The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B‐cell and diffuse large B‐cell histologies , 2002, British journal of haematology.

[28]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[29]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[30]  G. Salles,et al.  Primary thyroid lymphoma is a heterogeneous disease. , 2002, The Journal of clinical endocrinology and metabolism.

[31]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[32]  R. Gascoyne,et al.  Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[34]  H. Schultz,et al.  Primary Thyroid Lymphoma: A Retrospective Analysis of Prognostic Factors and Treatment Outcome for Localized Intermediate and High Grade Lymphoma , 2001, American journal of clinical oncology.

[35]  J. Cox,et al.  Localized non‐Hodgkin lymphoma involving the thyroid gland , 2001, Cancer.

[36]  C. Ross,et al.  A reassessment of primary thyroid lymphoma: high‐grade MALT‐type lymphoma as a distinct subtype of diffuse large B‐cell lymphoma , 2000, Histopathology.

[37]  L. Thompson,et al.  Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. , 2000, The American journal of surgical pathology.

[38]  F. Cavalli,et al.  Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[40]  Singer Ja.  Primary lymphoma of the thyroid. , 1998 .

[41]  K. Kita,et al.  gamma/delta T-cell lymphoma of the thyroid gland. , 1997, The New England journal of medicine.

[42]  H. Gogas,et al.  T-cell lymphoma in Hashimoto's thyroiditis. , 1996, Histopathology.

[43]  N. T. Pedersen,et al.  Primary non‐Hodgkin's lymphoma of the thyroid gland: a population based study , 1996, Histopathology.

[44]  Y. Shibamoto,et al.  Non-Hodgkin's lymphoma of the thyroid. A clinical study of twenty-two cases. , 1996, Acta oncologica.

[45]  J. Monchik,et al.  Role of surgery in stage IE non-Hodgkin's lymphoma of the thyroid. , 1994, Surgery.

[46]  A. Levis,et al.  P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  S. Tucker,et al.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  M. Tiemann,et al.  [Intensification of sensitivity of monoclonality determination of B-cells in autoimmune thyroiditis and low malignancy B-NHL of the MALT type using temperature gradient gel electrophoresis (TGGE)]. , 1994, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[49]  J. Jekel,et al.  Thyroid lymphoma. The case for combined modality therapy. , 1994, Cancer.

[50]  R. Tsang,et al.  Non-hodgkin's lymphoma of the thyroid gland: Prognostic factors and treatment outcome , 1993 .

[51]  I. Narabayashi,et al.  Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. , 1993, Thyroid : official journal of the American Thyroid Association.

[52]  R. Tsang,et al.  Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group. , 1993, International journal of radiation oncology, biology, physics.

[53]  J. Armitage.  The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. , 1991, Annals of Oncology.

[54]  A. Nonomura,et al.  Primary lymphoma of the thyroid: a clinical, histological and immunohistochemical study of 20 cases , 1990, Histopathology.

[55]  S. Nagataki,et al.  Hashimoto's thyroiditis manifesting monoclonal lymphocytic infiltration , 1990, Clinical and experimental immunology.

[56]  A. Huang,et al.  Extranodal head and neck lymphoma. Prognosis and patterns of recurrence. , 1990, Archives of otolaryngology--head & neck surgery.

[57]  F. Ganzina,et al.  Epirubicin in Combination Chemotherapy in the Treatment of Advanced Stage Non-Hodgkin's Lymphomas , 1987, Tumori.

[58]  A. Miyauchi,et al.  Malignant lymphomas of the thyroid gland: Analysis of 79 patients with emphasis on histologic prognostic factors , 1986, Cancer.

[59]  D. Wright,et al.  Primary malignant lymphoma of the thyroid--a tumour of mucosa-associated lymphoid tissue: review of seventy-six cases. , 1985, Histopathology.

[60]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[61]  A. Szekeres,et al.  Primary lymphoma of the thyroid. , 1982, Postgraduate medicine.

[62]  C. Coltman,et al.  Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.

[63]  S. Rosenberg,et al.  Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non‐Hodgkin's lymphomas , 1976, Cancer.

[64]  J. Berg,et al.  Occurrence and prognosis of extranodal lymphomas , 1972, Cancer.

[65]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[66]  D.,et al.  Regression Models and Life-Tables , 2022 .